Clinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies
Intrahepatic cholangiocarcinoma (ICCA) is a rare and aggressive malignant tumor that arises from the biliary tracts in the liver. Upfront surgery with adjuvant capecitabine in patients with resectable disease is often the standard treatment. Unfortunately, only 20% of patients present with resectabl...
Main Authors: | Samantha M. Ruff, Timothy M. Pawlik |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1321683/full |
Similar Items
-
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
by: Alessandro Rizzo
Published: (2021-05-01) -
Biomarkers of intrahepatic cholangiocarcinoma: diagnosis and response to therapy
by: Zachary J. Brown, et al.
Published: (2022-03-01) -
The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting
by: Salati M, et al.
Published: (2021-10-01) -
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
by: Giovanni Brandi, et al.
Published: (2023-04-01) -
Conversion therapy of intrahepatic cholangiocarcinoma
by: Wang Zhiwei, et al.
Published: (2020-12-01)